Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | CTSV | O60911 | 3/20 | 0.47 |
| ▸ | CTSL | P07711 | 3/20 | 0.47 |
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TERT | O14746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797234 | 0.95 | DRD3 (0.49) | CTSVCTSLPARP1DRD3KMT2A | |
| SCHEMBL1792996 | 0.95 | HSD17B10 (0.51) | KDM4EALDH1A1HSD17B10HPGDCTSV | |
| SCHEMBL1791923 | 0.94 | DRD3 (0.50) | KDM4EALDH1A1HSD17B10HPGDCTSV | |
| SCHEMBL1796162 | 0.91 | PARP1 (0.55) | KDM4EALDH1A1HSD17B10HPGDCTSV | |
| SCHEMBL1796400 | 0.90 | MAOA (0.46) | KDM4EALDH1A1HSD17B10HPGDPARP1 | |
| SCHEMBL1797107 | 0.88 | KDM4E (0.52) | KDM4EALDH1A1HSD17B10HPGDCTSV | |
| SCHEMBL1796653 | 0.88 | DRD3 (0.54) | CTSVCTSLPARP1DRD3SIGMAR1 | |
| SCHEMBL1797716 | 0.87 | PARP1 (0.48) | KDM4EALDH1A1HSD17B10HPGDPARP1 | |
| SCHEMBL1798443 | 0.87 | MAOA (0.50) | PARP1DRD3KMT2AMAPTCHRNA7 | |
| SCHEMBL1800692 | 0.86 | MAOA (0.54) | KDM4EALDH1A1HSD17B10HPGDCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | claimed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | claimed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | claimed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | claimed |
| US-7951791-B2 | e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders | ABBOTT LABORATORIES (US) | 2011-05-31 | — | — | US | disclosed |
| EP-2258682-A2 | Amino-substituted tricyclic derivatives and methods of use | Abbott Laboratories (US) | 2010-12-08 | — | — | EP | disclosed |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | US | disclosed |
| US-7365193-B2 | Amino-substituted tricyclic derivatives and methods of use | ABBOTT LABORATORIES (US) | 2008-04-29 | — | — | US | disclosed |
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | ABBVIE INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | SCHRIMPF MICHAEL R (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234031-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRNA1, CHRM1, GALR1 | KDM4E 2818/4885ALDH1A1 1267/4885HSD17B10 2037/4885 |
| US-20080161281-A1 | Amino-Substituted Tricyclic Derivatives and Methods of Use | CHRNA1, CHRM1, CHRNB1 | KDM4E 2402/4885ALDH1A1 1618/4885HSD17B10 2257/4885 |
| US-20050171079-A1 | Amino-substituted tricyclic derivatives and methods of use | CHRM1, CHRM3, CHRNA1 | KDM4E 2270/4885ALDH1A1 1103/4885HSD17B10 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.